Open-label pilot study of genetically engineered NY-ESO-1–specific t cells (GSK3377794) alone or in combination with pembrolizumab in relapsed/refractory multiple myeloma.

Aaron P. Rapoport,James E. Hoffman,Jonathan L. Kaufman,Kristin Blouch,Emily Butler,Maurice P. Deyoung,Benedetto Farsaci,Aisha N. Hasan,Andrew P. Holmes,Anne Huff,Amit Jain,Michael Jon Chisamore,Taiga Nishihori

Open-label pilot study of genetically engineered NY-ESO-1–specific t cells (GSK3377794) alone or in combination with pembrolizumab in relapsed/refractory multiple myeloma.

2020

Aaron P. Rapoport
James E. Hoffman
Jonathan L. Kaufman
Kristin Blouch
Emily Butler
Maurice P. Deyoung
Benedetto Farsaci
Aisha N. Hasan
Andrew P. Holmes
Anne Huff
Amit Jain
Michael Jon Chisamore
Taiga Nishihori

TPS8555Background: Adoptive cellular therapy may be practice-changing in relapsed/refractory multiple myeloma (MM). NY-ESO-1 TCR T (GSK3377794) are autologous polyclonal T cells transduced by a sel...

Keywords:

Oncology
Internal medicine
Multiple myeloma
genetically engineered
open label
Pathology
Pembrolizumab
relapsed refractory
Medicine
NY-ESO-1

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations